



Universiteit
Leiden
The Netherlands

Preclinical optimization of melanoma treatment

Hooijkaas, A.I.

Citation

Hooijkaas, A. I. (2013, June 13). *Preclinical optimization of melanoma treatment*. Retrieved from <https://hdl.handle.net/1887/20973>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/20973>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20973> holds various files of this Leiden University dissertation.

Author: Hooijkaas, Anna Irene

Title: Preclinical optimization of melanoma treatment

Issue Date: 2013-06-13

PRECLINICAL OPTIMIZATION OF MELANOMA TREATMENT

Anna Hooijkaas

ISBN: 978-94-6182-257-4

The research described in this thesis was performed at the Division of Immunology at the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (NKI-AvL), Amsterdam, The Netherlands.

The printing of this thesis was financially supported by the NKI-AvL, Bayer and Boehringer Ingelheim.

Layout and printing by Off Page, Amsterdam.

Copyright© 2013 by Anna Hooijkaas. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without permission of the author and the publisher holding the copyright of the articles.

PRECLINICAL OPTIMIZATION OF MELANOMA TREATMENT

Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. dr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 13 juni 2013
klokke 16:15 uur

door

Anna Hooijkaas
geboren te Leidschendam
in 1985

PROMOTIECOMMISSIE

Promotor: Prof. Dr. T.N.M. Schumacher

Co-promotor: Dr. C.U. Blank (NKI-AvL)

Overige leden:
Prof. Dr. J.B.A.G. Haanen
Prof. Dr. C.J.M. Melief
Prof. Dr. S.H. van der Burg
Prof. Dr. W.J. Mooi (VUmc)
Prof. Dr. R. Offringa (DKFZ, Duitsland)

*Voor mijn familie,
Voor Bastiaan*

CONTENTS

Chapter 1	General Introduction	9
Chapter 2	Combination of targeted therapy and immunotherapy in melanoma	25
Chapter 3	Overall survival and PD-L1 expression in metastasized malignant melanoma	49
Chapter 4	Expression of the embryological morphogen Nodal in stage III/IV melanoma	67
Chapter 5	Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy	89
Chapter 6	Synchronous BRAF ^{V600E} and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin-toxicity	119
Chapter 7	Targeting BRAF ^{V600E} in an inducible murine model of melanoma	135
Chapter 8	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma	159
Chapter 9	Summarizing Discussion	181
Addendum	Nederlandse samenvatting	201
	Curriculum Vitae	209
	List of publications	211

